Paper41205697
Classification system proposed to guide the design, development, regulatory approval, and scaling of long acting, small- and macro-molecule parenteral products (CS-BLAP).
Perazzolo S and 2 others. J Pharm Sci, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Classification system proposed to guide the design, development, regulatory approval, and scaling of long acting, small- and macro-molecule parenteral products (CS-BLAP). Papers, record 41205697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41205697
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Classification system proposed to guide the design, development, regulatory approval, and scaling of long acting, small- and macro-molecule parenteral products (CS-BLAP).
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Delayed-Action Preparations | Major topic |
| Drug Approval | Major topic |
| Drug Development | Major topic |
| Biological Products | Major topic |
| Humans | |
| Biopharmaceutics | |
| Particle Size | |
| Drug Delivery Systems | |
| Drug Design | |
| Pharmaceutical Preparations |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U01 AI148055 | NIAID NIH HHS | United States | U01AI148055 | PubMed | NIH RePORTER |
| U01 HL152401 | NHLBI NIH HHS | United States | U01HL152401 | PubMed | NIH RePORTER |
| R01 AI179309 | NIAID NIH HHS | United States | R01AI179309 | PubMed | NIH RePORTER |
| UM1 AI120176 | NIAID NIH HHS | United States | UM1AI120176 | PubMed | NIH RePORTER |
| R33 AI149665 | NIAID NIH HHS | United States | R33AI149665 | PubMed | NIH RePORTER |
| R61 AI149665 | NIAID NIH HHS | United States | R61AI149665 | PubMed | NIH RePORTER |
References77
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33166693 | Long-acting drugs and formulations for the treatment and prevention of HIV infection. | Int J Antimicrob Agents | 2021 | https://conductscience.org/library/papers/33166693 | PubMed |
| 2 | 11259830 | Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. | Adv Drug Deliv Rev | 2001 | https://conductscience.org/library/papers/11259830 | PubMed |
| 3 | 37901442 | A biomimetic chip to assess subcutaneous bioavailability of monoclonal antibodies in humans. | PNAS Nexus | 2023 | https://conductscience.org/library/papers/37901442 | PubMed |
| 4 | 22411683 | Dermal clearance model for epidermal bioavailability calculations. | J Pharm Sci | 2012 | https://conductscience.org/library/papers/22411683 | PubMed |
| 5 | 37508373 | Solute Transport across the Lymphatic Vasculature in a Soft Skin Tissue. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/37508373 | PubMed |
| 6 | 7988303 | Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. | Diabetes Care | 1994 | https://conductscience.org/library/papers/7988303 | PubMed |
| 7 | 22811424 | Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. | Physiol Rev | 2012 | https://conductscience.org/library/papers/22811424 | PubMed |
| 8 | 40956864 | The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases. | Annu Rev Pharmacol Toxicol | 2026 | https://conductscience.org/library/papers/40956864 | PubMed |
| 9 | 10215751 | The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency. | Br J Clin Pharmacol | 1999 | https://conductscience.org/library/papers/10215751 | PubMed |
| 10 | 11489331 | The physiology of the lymphatic system. | Adv Drug Deliv Rev | 2001 | https://conductscience.org/library/papers/11489331 | PubMed |
| 11 | 35361288 | Editorial: Towards a better understanding of the physiology of the lymphatics. | Inflamm Regen | 2022 | https://conductscience.org/library/papers/35361288 | PubMed |
| 12 | 25122564 | Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. | Drug Metab Dispos | 2014 | https://conductscience.org/library/papers/25122564 | PubMed |
| 13 | 25100673 | Subcutaneous absorption of biotherapeutics: knowns and unknowns. | Drug Metab Dispos | 2014 | https://conductscience.org/library/papers/25100673 | PubMed |
| 14 | 29388438 | Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities. | J Drug Target | 2018 | https://conductscience.org/library/papers/29388438 | PubMed |
| 15 | 26886328 | Clarifications: Dermal Clearance Model for Epidermal Bioavailability Calculations. | J Pharm Sci | 2016 | https://conductscience.org/library/papers/26886328 | PubMed |
| 16 | 30121315 | Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates. | J Pharm Sci | 2018 | https://conductscience.org/library/papers/30121315 | PubMed |
| 17 | 31031702 | The Discovery and Development of Liraglutide and Semaglutide. | Front Endocrinol (Lausanne) | 2019 | https://conductscience.org/library/papers/31031702 | PubMed |
| 18 | 3321914 | Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. | Acta Physiol Scand | 1987 | https://conductscience.org/library/papers/3321914 | PubMed |
| 19 | 26932471 | Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide. | In Silico Pharmacol | 2016 | https://conductscience.org/library/papers/26932471 | PubMed |
| 20 | 29665381 | A Refined Developability Classification System. | J Pharm Sci | 2018 | https://conductscience.org/library/papers/29665381 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42084126 | A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks. | AIDS | 2026 | https://conductscience.org/library/papers/42084126 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41205697
GET https://conductscience.org/api/papers/v1/41205697/references?page=2